Cargando…
Normal reference ranges for urinary δ‐aminolevulinic acid and porphobilinogen levels
Acute hepatic porphyria (AHP) is a family of rare, serious, and potentially life‐threatening metabolic disorders caused by mutations in genes encoding enzymes involved in hepatic heme biosynthesis. AHP is characterized by accumulation of neurotoxic heme intermediates, δ‐aminolevulinic acid (ALA), an...
Autores principales: | Agarwal, Sagar, Habtemarium, Bahru, Xu, Yuanxin, Simon, Amy R., Kim, Jae B., Robbie, Gabriel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802627/ https://www.ncbi.nlm.nih.gov/pubmed/33473344 http://dx.doi.org/10.1002/jmd2.12173 |
Ejemplares similares
-
ALAD Inhibition
by Porphobilinogen Rationalizes the
Accumulation of δ-Aminolevulinate in Acute Porphyrias
por: San Juan, Itxaso, et al.
Publicado: (2022) -
Derivative Matrix-Isopotential Synchronous Spectrofluorimetry and Hantzsch Reaction: A Direct Route to Simultaneous Determination of Urinary δ-Aminolevulinic Acid and Porphobilinogen
por: Ajmal, Muhammad, et al.
Publicado: (2022) -
Pharmacokinetic‐pharmacodynamic model of urinary δ‐aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria
por: Lee, Jongtae, et al.
Publicado: (2023) -
Enigmatic Evolutionary History of Porphobilinogen Deaminase in Eukaryotic Phototrophs
por: Oborník, Miroslav
Publicado: (2021) -
Prenatal Exposure to Lead, δ-Aminolevulinic Acid, and Schizophrenia: Further Evidence
por: Opler, Mark G.A., et al.
Publicado: (2008)